AccScience Publishing / CP / Online First / DOI: 10.36922/CP026290043
Cite this article
34
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

Cancer risk in congenital heart disease survivors: The need for long-term screening strategies

Josephine Ushang Adie1*
Show Less
1 Department of Public Health and Healthcare, Faculty of Preventive Medicine, First Moscow State Medical University, Moscow , Russia
Received: 14 July 2026 | Revised: 14 September 2026 | Accepted: 13 October 2026 | Published online: 11 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Improved survival in congenital heart disease (CHD) has shifted attention toward acquired conditions that emerge across the life course, including cancer. This structured narrative review updates epidemiologic, mechanistic, and surveillance evidence through 2025 and proposes a practical framework for clinical risk assessment. A 2025 systematic review and meta-analysis of six observational studies involving 276,124 participants reported a pooled cancer hazard ratio of 1.71 (95% confidence interval: 1.28–2.28); the estimate remained elevated after adjustment for chromosomal abnormalities (1.54, 95% confidence interval: 1.24–1.91), although between-study heterogeneity was substantial. Large registry studies show that risk is not uniform: it is influenced by age, CHD complexity, early procedures, genetic syndromes, transplantation, and cumulative medical exposure. Potential mechanisms include ionizing radiation, chronic hypoxemia with hypoxia-inducible factor signaling and oxidative stress, Fontan-associated hepatic congestion and fibrosis, altered immune surveillance after thymectomy, shared developmental genetics, and modifiable lifestyle factors. No broad CHD-specific cancer screening guideline currently exists. This review therefore proposes a three-tier surveillance algorithm that preserves standard population screening for most survivors, adds structured annual risk review for those with cumulative exposures or complex physiology, and applies condition-specific surveillance for clearly defined high-risk groups, particularly Fontan-associated liver disease and genetic syndromes. The proposed framework is intended for prospective validation rather than immediate replacement of established national screening guidelines.

Keywords
Congenital heart disease
Cancer risk
Survivorship
Screening
Radiation exposure
Fontan-associated liver disease
Cardio-oncology
Funding
None.
Conflict of interest
The author declares she has no competing interests.
References
  1. Downing KF, Nembhard WN, Rose CE, et al. Survival from birth until young adulthood among individuals with congenital heart defects: CH STRONG. Circulation. 2023;148(7):575-588. doi: 10.1161/CIRCULATIONAHA.123.064400
  2. Mandalenakis Z, Karazisi C, Skoglund K, et al. Risk of cancer among children and young adults with congenital heart disease compared with healthy controls. JAMA Netw Open. 2019;2(7):e196762. doi: 10.1001/jamanetworkopen.2019.6762
  3. Karazisi C, Dellborg M, Mellgren K, et al. Risk of cancer in young and older patients with congenital heart disease and the excess risk of cancer by syndromes, organ transplantation and cardiac surgery: Swedish health registry study (1930-2017). Lancet Reg Health Eur. 2022;18:100407. doi: 10.1016/j.lanepe.2022.100407
  4. Ren L, Feng M, Luo Y, Chen Y. Risk of cancer in patients with congenital heart disease: a systematic review and meta-analysis. Cardiology. 2025;150(3):303-310. doi: 10.1159/000540443
  5. Kampitsi CE, Mogensen H, Feychting M, Tettamanti G. The relationship between congenital heart disease and cancer in Swedish children: a population-based cohort study. PLoS Med. 2022;19(2):e1003903. doi: 10.1371/journal.pmed.1003903
  6. Hasan MS, Ganni E, Liu A, et al. CanCHD study of hematopoietic cancers in children with and without genetic syndromes. J Am Heart Assoc. 2024;13(1):e026604. doi: 10.1161/JAHA.122.026604
  7. Kang D, Choi GJ, Heo J, et al. Risk of cancer in newborns with congenital heart disease and their mothers: a nationwide cohort study. Circulation. 2025;151(11):807-809. doi: 10.1161/CIRCULATIONAHA.124.071811
  8. Kampitsi CE, Kenborg L, Mogensen H, et al. Mortality after cancer diagnosis among children with congenital heart disease in Denmark and Sweden. J Natl Cancer Inst. 2025;117(6):1134-1141. doi: 10.1093/jnci/djaf010
  9. Gurvitz M, Ionescu-Ittu R, Guo L, et al. Prevalence of cancer in adults with congenital heart disease compared with the general population. Am J Cardiol. 2016;118(11):1742-1750. doi: 10.1016/j.amjcard.2016.08.057
  10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
  11. Cohen S, Liu A, Gurvitz M, et al. Exposure to low-dose ionizing radiation from cardiac procedures and malignancy risk in adults with congenital heart disease. Circulation. 2018;137(13):1334-1345. doi: 10.1161/CIRCULATIONAHA.117.029138
  12. Campolo J, Annoni G, Giaccardi M, Andreassi MG. Congenital heart disease and the risk of cancer: an update on the genetic etiology, radiation exposure damage, and future research strategies. J Cardiovasc Dev Dis. 2022;9(8):245. doi: 10.3390/jcdd9080245
  13. Andreassi MG. Radiation risk from pediatric cardiac catheterization: friendly fire on children with congenital heart disease. Circulation. 2009;120(19):1847-1849. doi: 10.1161/CIRCULATIONAHA.109.904458
  14. Rey-Keim S, Schito L. Origins and molecular effects of hypoxia in cancer. Semin Cancer Biol. 2024;106-107:166-178. doi: 10.1016/j.semcancer.2024.10.001
  15. Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024;3(1):e000154. doi: 10.1136/bmjonc-2023-000154
  16. Téllez L, Payancé A, Tjwa E, et al. EASL-ERN position paper on liver involvement in patients with Fontan-type circulation. J Hepatol. 2023;79(5):1270-1301. doi: 10.1016/j.jhep.2023.07.013
  17. Emamaullee J, Zaidi AN, Schiano T, et al. Fontan-associated liver disease: screening, management, and transplant considerations. Circulation. 2020;142(6):591-604. doi: 10.1161/CIRCULATIONAHA.120.045597
  18. Cavalcanti NV, Palmeira P, Jatene MB, de Barros Dorna M, Carneiro-Sampaio M. Early thymectomy is associated with long-term impairment of the immune system: a systematic review. Front Immunol. 2021;12:774780. doi: 10.3389/fimmu.2021.774780
  19. Kooshesh KA, Foy BH, Sykes DB, Gustafsson K, Scadden DT. Health consequences of thymus removal in adults. N Engl J Med. 2023;389(5):406-417. doi: 10.1056/NEJMoa2302892
  20. Morton SU, Shimamura A, Newburger PE, et al. Association of damaging variants in genes with increased cancer risk among patients with congenital heart disease. JAMA Cardiol. 2021;6(4):457-462. doi: 10.1001/jamacardio.2020.4947
  21. Marlow EC, Ducore J, Kwan ML, et al. Leukemia risk in a cohort of 3.9 million children with and without Down syndrome. J Pediatr. 2021;234:172-180.e3. doi: 10.1016/j.jpeds.2021.03.001
  22. Willinger L, Brudy L, Meyer M, Oberhoffer-Fritz R, Ewert P, Müller J. Overweight and obesity in patients with congenital heart disease: a systematic review. Int J Environ Res Public Health. 2021;18(18):9931. doi: 10.3390/ijerph18189931
  23. Dua JS, Cooper AR, Fox KR, Graham Stuart A. Physical activity levels in adults with congenital heart disease. Eur J Cardiovasc Prev Rehabil. 2007;14(2):287-293. doi: 10.1097/HJR.0b013e32808621b9
  24. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918-1930. doi: 10.1001/jama.2024.5534
  25. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi: 10.1001/jama.2021.6238
  26. US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi: 10.1001/jama.2021.1117
  27. Gurvitz M, Krieger EV, Fuller S, et al. 2025 ACC/AHA/HRS/ISACHD/SCAI guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(7):822-976. doi: 10.1016/j.jacc.2025.09.006
  28. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466
  29. National Health Service. NHS screening. Accessed September 10, 2026. https://www.nhs.uk/tests-and-treatments/nhs-screening/
  30. Canadian Task Force on Preventive Health Care. Published guidelines. Accessed September 10, 2026. https://canadiantaskforce.ca/guidelines/published-guidelines/
  31. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63. doi: 10.7326/M14-0697
  32. Roos-Hesselink JW, Pelosi C, Brida M, et al. Surveillance of adults with congenital heart disease: current guidelines and actual clinical practice. Int J Cardiol. 2024;407:132022. doi: 10.1016/j.ijcard.2024.132022
  33. Freilinger S, Kaemmerer H, Pittrow RD, et al. PATHFINDER-CHD: prospective registry on adults with congenital heart disease, abnormal ventricular function, and/or heart failure as a foundation for establishing rehabilitative, prehabilitative, preventive, and health-promoting measures: rationale, aims, design and methods. BMC Cardiovasc Disord. 2024;24:181. doi: 10.1186/s12872-024-03833-y
Share
Back to top
Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing